Quantcast

Industry news that matters to you.  Learn more

Archives for April 2015

GATC Biotech Signs a Sales and Marketing Agreement for Products and Services With Molecular Health

GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, recently announced that it has signed a commercial agreement with Molecular Health. Under this agreement, GATC Biotech will make TreatmentMAP available to patients worldwide. The initial plans of the commercial collaboration are to market and support Molecular Health’s state-of-the-art system for tumour profiling.

Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, recently launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program’s goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers.

Genetic Variance Explains Poor Response to Common Asthma Medications

Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment – currently the most effective treatment for chronic asthma and acute asthma attack.

Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”

Rosetta Genomics to Acquire PersonalizeDx

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, recently announced that it has agreed to acquire CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation, a Fjord Ventures portfolio company. The acquisition of PersonalizeDx by Rosetta Genomics is expected to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.